Adults (including elderly patients): The recommended dose is 50 mg once daily with or without food.
Posology: Special populations: Renal and hepatic impairment: Mirabegron (Betmiga) has not been studied in patients with end stage renal disease (GFR < 15 mL/min/1.73 m2 or patients requiring haemodialysis) or severe hepatic impairment (Child-Pugh Class C) and it is therefore not recommended for use in these patient populations (see Pharmacology: Pharmacodynamics under Actions and Precautions).
Table 4 as follows provides the daily dosing recommendations for subjects with renal or hepatic impairment in the absence and presence of strong CYP3A inhibitors (see Pharmacology: Pharmacodynamics under Action, Precautions and Interactions).
Click on icon to see table/diagram/image
Gender: No dose adjustment is necessary according to gender.
Paediatric population: The safety and efficacy of Mirabegron (Betmiga) in children below 18 years of age have not yet been established. No data are available.
Method of administration: The tablet is to be taken once daily, with liquids, swallowed whole and is not to be chewed, divided, or crushed.